Thus, our findings suggest that the EGFR inhibitors may potentially facilitate anti-tumor adaptive immune responses by breaking tolerance especially in lung cancers with sensitizing EGFR mutations or EGFR overexpression that are associated with over-expression of PD-L1. The gene discussed is CD274; the disease is neoplasm.